Integrated safety summary for trifluridine/tipiracil (TAS-102)

Alfredo Falcone, Atsushi Ohtsu, Eric Van Cutsem, Robert J. Mayer, Michele Buscaglia, Johanna C. Bendell, Scott Kopetz, Paul Bebeau, Takayuki Yoshino

Research output: Contribution to journalArticlepeer-review


Trifluridine/tipiracil, an oral treatment combining trifluridine (an antineoplastic thymidine-based nucleoside analog) and tipiracil hydrochloride (a thymidine phosphorylase inhibitor), led to significant improvement in overall survival in metastatic colorectal cancer (mCRC) patients refractory to standard therapy in the phase III RECOURSE trial. Here, we report an integrated summary of the safety of trifluridine/ tipiracil. The main safety analysis includes integrated data from the RECOURSE and J003 studies (safety data group 2) of patients with refractory mCRC receiving trifluridine/ tipiracil at the recommended starting dose: 35 mg/m2 twice daily for 5 days with 2 days’ rest for 2 weeks, followed by a 14-day rest (one cycle). Integrated data from a larger group of mCRC patients receiving trifluridine/tipiracil at the recommended starting dose (group 1) and nonintegrated data on serious adverse events (SAEs) representing all clinical experience with trifluridine/tipiracil as of the data cutoff date (group 3) are also summarized. In group 2, myelosuppressive and all-grade gastrointestinal adverse events (AEs) were more frequent in trifluridine/tipiracil patients than in placebo patients. The trifluridine/tipiracil and placebo patients had similar frequencies of AEs leading to discontinuation (9.0 vs. 11.5%) and SAEs (27.7 vs. 29.2%); fatal AEs were more frequent in placebo patients than in trifluridine/tipiracil patients (9.3 vs. 2.8%). AEs leading to interruptions/delays/reductions were more frequent in trifluridine/tipiracil patients (56.3 vs. 12.7%). Trifluridine/ tipiracil was generally well tolerated, but over 50% of patients required interruptions/delays/reductions. There was a low rate of discontinuations, SAEs, and fatal AEs. This analysis confirms the safety profile observed in RECOURSE.

Original languageEnglish
Pages (from-to)89-96
Number of pages8
JournalAnti-Cancer Drugs
Issue number1
Publication statusPublished - Jan 1 2018


  • Pooled safety analysis
  • Safety profile
  • Trifluridine/tipiracil

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research


Dive into the research topics of 'Integrated safety summary for trifluridine/tipiracil (TAS-102)'. Together they form a unique fingerprint.

Cite this